- 1946~1989
- 1990~2001
- 2002~2007
- 2008~2010
- 2011~2013
- 2014~2016
1946~1989
1946~1989
1946
07
Acquired Hanseong Pharmaceutical Company(漢城藥館), and established Gongsin Pharmaceutical Company(共信藥業社) after obtaining the approval from Hanji Medicine Corporation(限地藥鍾商)
1957
05
Obtained the license for pharmaceutical business, and established Seonrim Pharmaceutical Company
07
Launched the digestive drug
1961
06
Renamed to Ilyang Pharmaceutical Industry Corporation
1971
07
Launched
12
Renamed to Ilyang Pharmaceutical Industry Co.,Ltd, and incorporated
1972
04
Selected as excellent pharmaceutical company on the Day of Health, and awarded the commendation from the Minister of Health and Welfare
1974
08
Listed on Korea Stock Exchange
1981
12
Exceeded $1 million in drug exports(total: $1,200,263)
1990~2001
1990~2001
1990
04
Launched
1991
05
Started the operation of State-of-the-art 1000BPM handmade production line at G.M.P factory in Yongin
05
Renamed to Ilyang Pharmaceutical Co., Ltd
1995
11
warded the Industrial Service Merit for reaching the milestone of 100 million
1996
03
Won the Gold Tower Industrial Medal on the 23rd Day of Commerce & Industry
09
Obtained the U.S. substance patent for the next-generation gastric ulcer treatment drug
10
Established TongHua IL-YANG (China)
1997
02
Obtained the U.S. and Japan substance patent for the liver disease treatment drug G009
1998
04
Obtained the U.S. patent for IY-81149, the next-generation anti-ulcer treatment drug
07
Established YangZhou IL-YANG (China)
2000
09
The authentic gGinseng drink received the Gold Prize in 2000 China International Food & Medicine Exhibition
2001
02
Entered into a contract with Baxter, the multinational company, for the exclusive sale of the essential drugs for patients in intensive care unit and emergency room
05
Exceeded KRW 10 billion in sales of "Hytrin", the prostatic hypertrophy treatment drug approved by KFDA, carving out the largest share in the market
12
Completed the construction of the nation’s only state-of-the-art BGMP inorganic synthesis factory with an annual production capacity of 2000 tons
12
Entered into the license agreement with China's Livzon for "IY81149"
2002~2007
2002~2007
2002
05
Obtained the U.S. patent for fine enteric coated granules
12
Acquired the domestic exclusive sales and goodwill for “Uprima Tab” the erectile dysfunction treatment drug of ABBOTT
2003
09
Awarded the Stone Order of Industrial Service Merit on the 9th Day of statistics
2004
02
BIO revolution - Simultaneous clinical progression for ILPRAZOLE in five countries worldwide
03
Exclusive domestic sale of RESPeRATE, the world’s only hypertension treatment instrument approved by the U.S. FDA
05
Entered into an exclusive license agreement with the U.S.-based Alliance for the OXIGENT, the artificial blood (it has excellent oxygen-carrying capacity and therefore can substitute the red blood cell transfusion)
2005
01
Released the Tong-sim-rak(通心絡), the new-concept herbal medicine for heart disease/angina/cardiovascular treatment
02
Obtained the German patent for the anti-ulcer injection formulation(phase 3 clinical trial is scheduled in 4 countries including Singapore)
04
Embarked on phase 3 clinical trial for “Ilaprazole”, the next-generation new material anti-ulcer agent (After the experiment following the multinational phase 2 clinical trial, an agreement was entered into with GCRC to conduct the global phase 3 clinical trial worldwide, including Korea)
06
eveloped the new leukemia treatment drug "IY-5511"
10
Developed raw material from Phellinus linteus mycelia for anti-malignant tumor agents
11
Successfully synthesized the Tamiflu, the bird flu treatment drug
2006
02
Completed the phase 3 clinical trial in China for "Ilaprazole", the next generation anti-ulcer agent
04
Submitted the application to China’s FDA for the approval of the sale of new drug, "Ilaprazole", the next generation anti-ulcer agent
2007
03
Successfully completed the animal experiment of Leukemia treatment drug "IY-5511”
08
Completed the phase 2 clinical trial in the United States for Ilaprazole
10
Completed the application for the approval of new drug, “Ilaprazole”
2008~2010
2008~2010
2008
04
Obtained the approval of Ilaprazole based on KFDA standards and the test method & finished manufactured product authorization
05
Obtained the DMF approval of Ilaprazole from KFDA
06
Obtained the KFDA approval of the phase 1 and 2 clinical trial(IND) for the next-generation leukemia treatment drug IY5511
07
Clinical trial of the next-generation leukemia treatment drug IY5511, conducted by Catholic University School of Medicine
08
Published the statistics analytical results of phase 3 clinical trial for Ilaprazole in six countries of Southeast Asia
09
Passed the KFDA’s safety effectiveness review of Ilaprazole, the next-generation anti-ulcer agent
10
Obtained the new drug approval for Ilaprazole "Noltec", which is the next-generation anti-ulcer agent and the nation’s 14th new indigenous drug
11
Research grant of KRW 3.8 billion, the largest for any single research project, for IY5511, the next-generation leukemia treatment drug
12
Established the SIS Immunology Research Center jointly in collaboration among Samsung Seoul Hospital, Ilyang Pharmaceutical, and Sookmyung Women's University
2009
03
Award the Grand Prize for "Noltec”, the next-generation anti-ulcer agent, in the category of new drug development
03
Obtained the U.S. patent for IY5511, the leukemia treatment drug
05
Kim Dong-yeon took the office of President
05
Extended the patent term of Ilaprazole, the next-generation anti-ulcer agent, to 2027
05
Supplied the raw materials of Ilaprazole, the next-generation anti-ulcer agent, exclusively to India-based Merck
06
Exported the finished pharmaceutical product to Indonesia, etc., under the name of Ilaprazole, the next-generation anti-ulcer agent
07
Succeeded in phase 1 clinical trial of “IY5511”, the leukemia treatment drug, and embarked on the global phase 2 clinical trial
12
Started the sale of "Noltec", the 14th new indigenous drug
12
Won the medal of excellence in 2009 National Research & Development Excellence"
2010
01
Acquired the healthy technology[HT] certification mark for Noltec
04
Discovered the Cytokine, the body defense system control & stimulus signal substance, for the first time
04
Obtained the approval of the phase 2 clinical trial(IND) in India and Thailand for IY5511, the next-generation leukemia treatment drug
04
Invented the new Peptide, the angiogenesis-promoting substances
05
Groundbreaking ceremony of vaccine manufacturing plant in Eumseong, Chungbuk
11
Ilyang Pharmaceutical developed the antiviral substances of new mechanism
12
Ilyang Pharmaceutical was designated to undertake the pilot project for new drug development and launched the 4 types of cytokines for research purpose
2011~2013
2011~2013
2011
02
Completed the registration of phase 3 clinical trial for anti-ulcer agent "Noltec” reflux esophagitis
04
Held the ceremony to mark the completion of the vaccine manufacturing plant in Eumseong, Chungbuk
05
『Obtained the approval of phase 3 clinical trial for "radotinib", the super leukemia treatment drug
07
Submitted the application for new drug status of "radotinib", the super leukemia treatment drug
07
Radotinib" was confirmed under the "WHO International Nonproprietary Name(INN)”
07
Obtained the U.S. patent for anti-ulcer agent "Ilaprazole"
08
Started the phase 3 clinical trial for "radotinib"
09
Obtained the substance patent of Canada and New Zealand for "radotinib"
2012
01
Obtained the final approval of "KFDA for Supect(ingredient name: radotinib), the super leukemia treatment drug
02
Ilyang Pharmaceutical developed “Supect”, Asia's first super leukemia treatment drug, won the Grand Prize in the 13th Korea Republic New Drug Development Award in the category of new drug development
03
SIS Immunology Research Center - Obtained the utilization patent for the invention of components that enhances the hair growth function using the fat stem cells
06
lyang Pharmaceutical won the "New Drug Grand Prize" in Osong New Drug Award
07
Ilyang Pharmaceutical, the mechanism of action completely different from the previous one Presented the super antiviral substance to the 2012 World Society for Virology for the first time,
09
Noltec, the anti-ulcer drug, completed the addition of the indication for reflux esophagitis
10
Entered into a contract with Dae-woong Pharmaceuticals for the domestic sale of “Supect”, Asia's first super leukemia treatment drug
10
Ilyang Pharmaceutical was awarded the commendation from the President on the 26th Day of Medicine
2013
01
Presented the results of phase II clinical trial of “Supect”, Asia's first super leukemia treatment drug, to the International Society of Hematology
02
Kim Dong-Yeon, the President, took office as Chairman of New Drug Association
03
Selection of antiviral substance IY7640 as study assignment of the government-affiliated “business unit of governmental department” against novel influenza
04
‘Supect’, the best estimation as study assignment supported by the Ministry of Health and Welfare
06
Conclusion of a term sheet of ‘Noltec’, ‘Supect’ with Abdi Ibrahim Pharmaceuticals in Turkey
06
Conclusion of MOU of production and sales of ‘Supect’ with Yangzhou Ilyang in China
08
Permission approval of a flu vaccine of Ilyang Pharmaceuticals from KFDA
08
Yongin factory, acquisition of the approval qualification as a foreign manufacturer for quasi-medicines from Japanese Ministry of Health, Labor and Welfare
08
‘Supect’ as a super leukemia medicine, selection in 100 items among excellent results from the national study and development
09
Conclusion of the exclusive sales and license contract of ‘Noltec’ as the antiulcer drug with Life Pharma Pharmaceuticals in UAE
10
Conclusion of a main contract of license of ‘Supect’ with Yangzhou Ilyang in China
12
Representative Kim Dong-Yeon, receiving the president prize as a man of merit of health and medical service technology promotion
2014~2016
2014~2016
2014
02
Conclusion of a main contract of “No1tec” with with Abdi Ibrahim Pharmaceuticals in Turkey
02
Completed the enrollment of patients in phase 3 clinical trial for SUPECT
02
정Government held “Transgovernmental Enterprise for Pandemic Influenza in Korea(TEPIK)” Contest In the Final Selection, a New Influenza Vaccine, H7N9 form, Selected as Research Project
03
Entered into the license agreement for ‘SUPECT’ with ABDI IBRAHIM pharmaceuticals, the number one pharmaceutical company in Turkey.
05
Respiratory Syncytial Virus(RSV) Treatment Substance Developed
05
MSA Signed with Quintiles, the Leading Global CRO
05
Term Sheet Signed with R-pharm, Russian Pharmaceutical Company
05
Registered Noltec Manufacturing Site as a GMP Complied Site by UAE/MoH
06
Term Sheet Signed with Ache, No. 1 Pharmaceutical Company in Brazil
09
‘YangZhou-Il-Yang’, ‘New EU-GMP Plant’ Dedication Ceremony.
10
Supect, Awarded the Grand Prize for Pharmaceutical Sector of Korea’s New Drug.
11
won the IR52 Jang Young-shil Award
12
won the 20 million USD Top Export Award
2015
01
Initiation of clinical trial phase 1/2a for quadrivalent inactivated Influenza Vaccine (egg-based)
02
SUPECT, early completion of multi-national/multi-center clinical trial phase 3
02
Approved market authorization for IL-YANG Flu Vaccine Vial INJ.(Trivalent inactivated influenza vaccine)
06
“SUPECT” validated as a potential treatment for Acute Myeloid Leukemia(AML)
06
Candidate material for New Drug confirms efficacy on “Ebola Virus”
07
Discover potential “MERS Virus” treatment substance
07
License Agreement for ‘NOLTEC’ signed with a Mexican pharmaceutical company, “Chinoin”
07
Super leukemia treatment SUPECT, applied for 1st line treatment
07
Memorandum Of Understanding(MOU) signed with Public research laboratory of National Medical Center(NMC)
08
Entered Term Sheet with BIOPAS of Columbia for SUPECT
10
Initiated Phase III Clinical trial for Quadrivalent Influenza Vaccine
10
Super leukemia treatment SUPECT approved for 1st line treatment
11
Completion ceremony of Chungbuk Jecheon EU-GMP facility
12
IL-YANG PHARM, awarded “Certificate of Minister of Ministry of Health” under recognition of great pharmaceutical product development merit
12
Mr. Il Hwi JUNG(Overseas Department) awarded “10 Most Influential Global Citizen in Jangsu” award from Jangsu Province of China
2016
01
IL-YANG PHARM’s Yongin Plant designated as “Yongin Urban High-Tech Industrial Complex”
02
SUPECT, Launching Ceremony for 1st Line Therapy
02
Yongin IlYangHippo Urban High-Tech Industrial Complex MOU
02
IL-YANG PHARM, MOU signed with Gyeongbuk Institute for Bio Industry
02
“NOLTEC”, New Anti-Ulcer Agent Drug – Marketing Authorization Approved in Ecuador
05
IL-YANG, entered MOU with Cha Vaccine R&D Center for cooperate R&D of Flu Vaccines and other New Vaccines.
05
Discovered an effective material for ‘Zika’ and ‘MERS’ virus treatment.
05
New influenza vaccine research project finally selected as governments’ “Infectious diseases crisis management technology development“ contest
06
SUPECT, signed License and Supply Agreement with Colombian company called BIOPAS
07
Development of MERS virus treatment, selected as governmental research project
08
Development of Parkinson diseases treatment with Johns Hopkins (USA) initiated.
09
NOLTEC, signed Licensing agreement signed with Russian company called R-PHARM.
09
Embryonic based Quadrivalent influenza vaccine approval by MFDS.